Methods of treating pain using protein solutions
AssigneeBiomet Biologics, LLC
InventorsKrista Toler, William King, Jennifer E. Woodell-May
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating pain in mammalian subjects are provided. The methods include obtaining blood or a fraction of blood from the subject, measuring a therapeutic indicator in the blood or in the fraction blood, and administering an anti-inflammatory composition to the subject if the therapeutic indicator is equal to or above a threshold level. The anti-inflammatory composition comprises a protein solution including interleukin-1 receptor antagonist. The protein solution may be prepared from the blood or blood fraction obtained from the subject.
Claims20
A method for treating osteoarthritis in a subject, the method comprising:
- obtaining blood or a fraction of blood;
- measuring a therapeutic indicator in a solution comprising the blood or fraction of blood, the therapeutic indicator selected from a concentration of interleukin-1 receptor antagonist (IL-1ra), a ratio of IL-ra concentration to interleukin-1 (IL-1) concentration, a concentration of white blood cells, a white blood cell count, or a combination thereof;
- and
- administering an anti-inflammatory composition to the subject, wherein the anti-inflammatory composition is prepared from the solution and comprises IL-1ra, soluble tumor necrosis factor-receptor I (sTNF-RI), soluble tumor necrosis factor-receptor II (sTNF-RII), epidermal growth factor-1 (EGF), platelet-derived growth factor-AB (PDGF-AB), platelet-derived growth factor-BB (PDGF-BB), vascular endothelial growth factor (VEGF), and transforming growth factor-β1 (TGF-β1), wherein the anti-inflammatory composition is effective for reducing or eliminating osteoarthritis pain in the subject when the therapeutic indicator is equal to or greater than a threshold level.
A method for treating osteoarthritis in a subject, comprising:
- providing or obtaining a solution comprising white blood cells, interleukin-1 receptor antagonist (IL-1ra), soluble tumor necrosis factor-receptor I (sTNF-RI), soluble tumor necrosis factor-receptor II (sTNF-RII), epidermal growth factor-1 (EGF), platelet-derived growth factor-AB (PDGF-AB), platelet-derived growth factor-BB (PDGF-BB), vascular endothelial growth factor (VEGF), and transforming growth factor-β1 (TGF-β1);
- measuring a concentration of interleukin-1 receptor antagonist (IL-1ra), a concentration ratio of IL-ra to interleukin-1 (IL-1), or a concentration of white blood cells, in the solution;
- and
- administering the solution to the subject, wherein the solution is effective to reduce osteoarthritis pain in the subject when the measuring detects a threshold level of the measured component.
A method for treating osteoarthritis in a subject, the method comprising:
- producing an autologous protein solution (APS) by contacting a solution comprising white blood cells obtained from the subject with a solid extraction material, wherein the APS comprises interleukin-1 receptor antagonist (IL-1ra), soluble tumor necrosis factor-receptor II (sTNF-RII), epidermal growth factor-1 (EGF), platelet-derived growth factor-AB (PDGF-AB), platelet-derived growth factor-BB (PDGF-BB), vascular endothelial growth factor (VEGF), transforming growth factor-β1 (TGF-β1), and interleukin 1 (IL-1);
- measuring at least one therapeutic indicator in the solution or in the APS, the therapeutic indicator selected from the concentration of IL-1ra, the ratio of the concentrations of IL-1ra:IL-1, a white blood cell concentration, or a combination thereof;
- and
- administering the APS to the subject, wherein the APS is effective for reducing or eliminating osteoarthritis pain in the subject when the at least one therapeutic indicator is equal to or greater than a threshold level.
Dependencies are inferred from the claim text.